TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Abera Bioscience AB
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Turnover |
0
|
2,646
|
0 |
| Financial expenses |
1
|
0
|
0 |
| Earnings before taxes |
-1,100
|
-16,717
|
-19,380 |
| EBITDA |
-1,059
|
-16,799
|
-19,393 |
| Total assets |
13,603
|
9,350
|
19,574 |
| Current assets |
10,647
|
7,438
|
17,686 |
| Current liabilities |
4,947
|
3,692
|
2,795 |
| Equity capital |
8,656
|
5,658
|
16,779 |
| - share capital |
1,228
|
1,157
|
1,033 |
| Employees (average) |
5
|
6
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Solvency |
63.6%
|
60.5%
|
85.7% |
| Turnover per employee |
0
|
441
|
0 |
| Profit as a percentage of turnover | -631.8% | ||
| Return on assets (ROA) |
-8.1%
|
-178.8%
|
-99.0% |
| Current ratio |
215.2%
|
201.5%
|
632.8% |
| Return on equity (ROE) |
-12.7%
|
-295.5%
|
-115.5% |
| Change turnover | |||
| Change turnover % | -100% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % |
0%
|
20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.